株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

API (原薬) の世界市場 - 2024年までの予測:革新的API、ジェネリックAPI

Active Pharmaceutical Ingredient/ API Market by Type (Innovative, Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), Product (mAb, Hormone, Biosimilar) Drug (OTC, Rx), Therapy, and Region - Global Forecast to 2024

発行 MarketsandMarkets 商品コード 225648
出版日 ページ情報 英文 255 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.86円で換算しております。
Back to Top
API (原薬) の世界市場 - 2024年までの予測:革新的API、ジェネリックAPI Active Pharmaceutical Ingredient/ API Market by Type (Innovative, Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), Product (mAb, Hormone, Biosimilar) Drug (OTC, Rx), Therapy, and Region - Global Forecast to 2024
出版日: 2019年01月07日 ページ情報: 英文 255 Pages
概要

世界のAPI (原薬) 市場は、2019年の1,822億米ドルから、2024年までに2,452億米ドルまで拡大すると見られています。市場は、2019年〜2024年のCAGR (複合年間成長率) で、6.1%の成長が予測されています。

当レポートでは、世界のAPI (原薬) 市場について調査分析し、市場概要、産業動向、セグメント別の市場分析、競合情勢、主要企業などについて、体系的な情報を提供しています。

FIGURE 13 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

  • API:市場概要
  • API市場:種類別
  • API市場:メーカーの種類別
  • API市場:合成の種類別
  • API市場:薬剤の種類別
  • 地域別スナップショット:API市場

第5章 市場概要

  • イントロダクション
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
    • 課題

第6章 APIの世界市場:種類別

  • イントロダクション
  • 革新的API
  • ジェネリックAPI

第7章 APIの世界市場:メーカーの種類別

  • イントロダクション
  • キャプティブAPIメーカー
  • マーチャントAPIメーカー

第8章 APIの世界市場:合成の種類別

  • イントロダクション
  • 合成API
  • バイオテクノロジーAPI

第9章 APIの世界市場:薬剤の種類別

  • イントロダクション
  • 処方薬
  • OTC薬
  • API市場:効能別

第10章 APIの世界市場:治療応用別

  • イントロダクション
  • 伝染性疾患
  • 腫瘍
  • 疼痛管理
  • 心血管疾患
  • 糖尿病
  • 呼吸器疾患
  • その他

第11章 APIの世界市場:地域別

  • イントロダクション
  • 北米
  • 欧州
  • アジア
  • その他

第12章 競合情勢

  • 概要
  • 市場企業ランキング
  • 競合リーダーシップマッピング
  • 競合状況と動向

第13章 企業プロファイル

  • PFIZER, INC.
  • NOVARTIS AG
  • SANOFI
  • BOEHRINGER INGELHEIM
  • BRISTOL-MYERS SQUIBB
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • ELI LILLY AND COMPANY
  • GLAXOSMITHKLINE PLC
  • MERCK & CO., INC.
  • ABBVIE INC.
  • F. HOFFMANN-LA ROCHE
  • ASTRAZENECA

第14章 付録

図表

LIST OF TABLES

  • TABLE 1 INDICATIVE LIST OF DRUGS GOING GENERIC IN 2018
  • TABLE 2 INDICATIVE LIST OF BIOLOGICS THAT GAINED REGULATORY APPROVAL IN THE US IN 2017-2018
  • TABLE 3 INDICATIVE LIST OF BIOSIMILARS THAT GAINED US REGULATORY APPROVAL IN 2018
  • TABLE 4 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 5 INDICATIVE LIST OF NEW MOLECULAR ENTITIES THAT GAINED US FDA APPROVAL IN 2018
  • TABLE 6 LIST OF MAJOR DRUGS SET TO LOSE PATENT PROTECTION IN 2018
  • TABLE 7 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 8 GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 9 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2017-2024 (USD BILLION)
  • TABLE 10 CAPTIVE API MANUFACTURERS MARKET, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 11 LIST OF SIGNIFICANT CMO/CDMO FACILITY EXPANSIONS
  • TABLE 12 MERCHANT API MANUFACTURERS MARKET, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 13 MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 14 MERCHANT INNOVATIVE API MANUFACTURERS MARKET, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 15 MERCHANT GENERIC API MANUFACTURERS MARKET, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 16 MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS 2017-2024 (USD BILLION)
  • TABLE 17 MERCHANT SYNTHETIC API MANUFACTURERS MARKET, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 18 MERCHANT BIOTECH API MANUFACTURERS MARKET, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 19 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 20 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 21 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE 2017-2024 (USD BILLION)
  • TABLE 22 INNOVATIVE SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 23 GENERIC SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 24 TOP SELLING BIOLOGICS (2018)
  • TABLE 25 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 26 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 27 INNOVATIVE BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 28 INDICATIVE LIST OF BIOSIMILARS THAT GAINED US FDA APPROVAL DURING 2017-2018
  • TABLE 29 GENERIC BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 30 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT 2017-2024 (USD BILLION)
  • TABLE 31 INDICATIVE LIST OF MONOCLONAL ANTIBODIES THAT RECEIVED FDA APPROVAL IN 2018
  • TABLE 32 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 33 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONES & GROWTH FACTORS, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 34 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CYTOKINES, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 35 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR FUSION PROTEINS, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 36 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT VACCINES, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 37 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR THERAPEUTIC ENZYMES, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 38 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BLOOD FACTORS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 39 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2017-2024 (USD BILLION)
  • TABLE 40 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 41 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 42 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR YEAST EXPRESSION SYSTEMS, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 43 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INSECT EXPRESSION SYSTEMS, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 44 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER EXPRESSION SYSTEMS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 45 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2017-2024 (USD BILLION)
  • TABLE 46 PRESCRIPTION DRUGS MARKET, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 47 OVER-THE-COUNTER DRUGS MARKET, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 48 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2017-2024 (USD BILLION)
  • TABLE 49 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2017-2024 (USD BILLION)
  • TABLE 50 INDICATIVE LIST OF US FDA-APPROVED DRUGS FOR COMMUNICABLE DISEASES (2018)
  • TABLE 51 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 52 INDICATIVE LIST OF US FDA-APPROVED DRUGS FOR ONCOLOGY (2018)
  • TABLE 53 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 54 INDICATIVE LIST OF US FDA-APPROVED DRUGS FOR PAIN MANAGEMENT (2018)
  • TABLE 55 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 56 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 57 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 58 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 59 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 60 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2017-2024 (USD BILLION)
  • TABLE 61 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2017-2024 (USD BILLION)
  • TABLE 62 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 63 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2017-2024 (USD BILLION)
  • TABLE 64 NORTH AMERICA: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 65 NORTH AMERICA: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 66 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 67 NORTH AMERICA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 68 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 69 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2017-2024 (USD BILLION)
  • TABLE 70 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2017-2024 (USD BILLION)
  • TABLE 71 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2017-2024 (USD BILLION)
  • TABLE 72 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2017-2024 (USD BILLION)
  • TABLE 73 INDICATIVE LIST OF RECENT FDA APPROVALS FOR DRUG DELIVERY PRODUCTS
  • TABLE 74 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 75 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2017-2024 (USD BILLION)
  • TABLE 76 US: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 77 US: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 78 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 79 US: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 80 US: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 81 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2017-2024 (USD BILLION)
  • TABLE 82 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2017-2024 (USD BILLION)
  • TABLE 83 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2017-2024 (USD BILLION)
  • TABLE 84 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 85 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2017-2024 (USD BILLION)
  • TABLE 86 CANADA: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 87 CANADA: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 88 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 89 CANADA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 90 CANADA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 91 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2017-2024 (USD BILLION)
  • TABLE 92 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2017-2024 (USD BILLION)
  • TABLE 93 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2017-2024 (USD BILLION)
  • TABLE 94 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2017-2024 (USD BILLION)
  • TABLE 95 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 96 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2017-2024 (USD BILLION)
  • TABLE 97 EUROPE: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 98 EUROPE: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 99 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 100 EUROPE: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 101 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 102 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2017-2024 (USD BILLION)
  • TABLE 103 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2017-2024 (USD BILLION)
  • TABLE 104 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2017-2024 (USD BILLION)
  • TABLE 105 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2017-2024 (USD BILLION)
  • TABLE 106 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 107 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2017-2024 (USD BILLION)
  • TABLE 108 GERMANY: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 109 GERMANY: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 110 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 111 GERMANY: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 112 GERMANY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 113 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2017-2024 (USD BILLION)
  • TABLE 114 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2017-2024 (USD BILLION)
  • TABLE 115 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2017-2024 (USD BILLION)
  • TABLE 116 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 117 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2017-2024 (USD BILLION)
  • TABLE 118 FRANCE: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 119 FRANCE: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 120 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 121 FRANCE: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 122 FRANCE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 123 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2017-2024 (USD BILLION)
  • TABLE 124 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2017-2024 (USD BILLION)
  • TABLE 125 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2017-2024 (USD BILLION)
  • TABLE 126 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 127 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2017-2024 (USD BILLION)
  • TABLE 128 UK: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 129 UK: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 130 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 131 UK: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 132 UK: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 133 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2017-2024 (USD BILLION)
  • TABLE 134 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2017-2024 (USD BILLION)
  • TABLE 135 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2017-2024 (USD BILLION)
  • TABLE 136 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 137 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2017-2024 (USD BILLION)
  • TABLE 138 ITALY: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 139 ITALY: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 140 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 141 ITALY: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 142 ITALY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 143 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2017-2024 (USD BILLION)
  • TABLE 144 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2017-2024 (USD BILLION)
  • TABLE 145 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2017-2024 (USD BILLION)
  • TABLE 146 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 147 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2017-2024 (USD BILLION)
  • TABLE 148 SPAIN: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 149 SPAIN: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 150 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 151 SPAIN: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 152 SPAIN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 153 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2017-2024 (USD BILLION)
  • TABLE 154 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2017-2024 (USD MILLION)
  • TABLE 155 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2017-2024 (USD MILLION)
  • TABLE 156 ROE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 157 ROE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2017-2024 (USD BILLION)
  • TABLE 158 ROE: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 159 ROE: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 160 ROE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 161 ROE: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 162 ROE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 163 ROE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2017-2024 (USD BILLION)
  • TABLE 164 ROE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2017-2024 (USD BILLION)
  • TABLE 165 ROE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2017-2024 (USD BILLION)
  • TABLE 166 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2017-2024 (USD BILLION)
  • TABLE 167 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 168 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2017-2024 (USD BILLION)
  • TABLE 169 ASIA: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 170 ASIA: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 171 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 172 ASIA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 173 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 174 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2017-2024 (USD MILLION)
  • TABLE 175 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2017-2024 (USD BILLION)
  • TABLE 176 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2017-2024 (USD BILLION)
  • TABLE 177 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2017-2024 (USD BILLION)
  • TABLE 178 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 179 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2017-2024 (USD BILLION)
  • TABLE 180 JAPAN: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 181 JAPAN: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 182 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 183 JAPAN: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 184 JAPAN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 185 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2017-2024 (USD BILLION)
  • TABLE 186 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2017-2024 (USD BILLION)
  • TABLE 187 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2017-2024 (USD BILLION)
  • TABLE 188 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 189 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2017-2024 (USD BILLION)
  • TABLE 190 CHINA: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 191 CHINA: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 192 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 193 CHINA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 194 CHINA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 195 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2017-2024 (USD BILLION)
  • TABLE 196 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2017-2024 (USD BILLION)
  • TABLE 197 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2017-2024 (USD BILLION)
  • TABLE 198 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 199 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2017-2024 (USD BILLION)
  • TABLE 200 INDIA: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 201 INDIA: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 202 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 203 INDIA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 204 INDIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 205 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2017-2024 (USD BILLION)
  • TABLE 206 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2017-2024 (USD BILLION)
  • TABLE 207 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2017-2024 (USD BILLION)
  • TABLE 208 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 209 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2017-2024 (USD BILLION)
  • TABLE 210 SOUTH KOREA: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 211 SOUTH KOREA: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 212 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 213 SOUTH KOREA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 214 SOUTH KOREA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 215 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2017-2024 (USD BILLION)
  • TABLE 216 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2017-2024 (USD BILLION)
  • TABLE 217 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2017-2024 (USD BILLION)
  • TABLE 218 ROA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 219 ROA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2017-2024 (USD BILLION)
  • TABLE 220 ROA: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 221 ROA: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 222 ROA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 223 ROA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 224 ROA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 225 ROA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2017-2024 (USD BILLION)
  • TABLE 226 ROA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2017-2024 (USD BILLION)
  • TABLE 227 ROA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2017-2024 (USD BILLION)
  • TABLE 228 ROW: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 229 ROW: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2017-2024 (USD BILLION)
  • TABLE 230 ROW: MERCHANT API MANUFACTURERS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 231 ROW: MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 232 ROW: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2017-2024 (USD BILLION)
  • TABLE 233 ROW: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 234 ROW: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2017-2024 (USD BILLION)
  • TABLE 235 ROW: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2017-2024 (USD BILLION)
  • TABLE 236 ROW: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2017-2024 (USD BILLION)
  • TABLE 237 ROW: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2017-2024 (USD BILLION)
  • TABLE 238 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET PLAYER RANKING, 2018
  • TABLE 239 PRODUCT LAUNCHES, 2016-2018
  • TABLE 240 EXPANSIONS, 2016-2018
  • TABLE 241 ACQUISITIONS, 2015-2018
  • TABLE 242 OTHER STRATEGIES, 2015-2018
  • TABLE 243 EXCHANGE RATE (UTILIZED FOR THE CONVERSION OF EUR TO USD)
  • TABLE 244 EXCHANGE RATE (UTILIZED FOR THE CONVERSION OF GBP TO USD)
  • TABLE 245 EXCHANGE RATES (UTILIZED FOR THE CONVERSION OF CHF TO USD)

LIST OF FIGURES

  • FIGURE 1 APIS: MARKET SEGMENTATION
  • FIGURE 2 RESEARCH DESIGN
  • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS
  • FIGURE 4 BOTTOM-UP APPROACH
  • FIGURE 5 TOP-DOWN APPROACH
  • FIGURE 6 DATA TRIANGULATION METHODOLOGY
  • FIGURE 7 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2019 VS. 2024 (USD BILLION)
  • FIGURE 8 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER, 2019 VS. 2024
  • FIGURE 9 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2019 VS. 2024
  • FIGURE 10 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2019 VS. 2024
  • FIGURE 11 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2019 VS. 2024
  • FIGURE 12 GEOGRAPHICAL SNAPSHOT OF THE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
  • FIGURE 13 INCREASING INCIDENCE OF CHRONIC DISEASES AND GROWING IMPORTANCE OF GENERICS ARE DRIVING MARKET GROWTH
  • FIGURE 14 GENERIC APIS TO GROW AT THE HIGHEST CAGR FROM 2019 TO 2024
  • FIGURE 15 MERCHANT API MANUFACTURERS SEGMENT TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD
  • FIGURE 16 ONCOLOGY SEGMENT TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 17 PRESCRIPTION DRUGS TO COMMAND THE LARGEST MARKET SHARE IN 2019
  • FIGURE 18 CHINA TO WITNESS THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
  • FIGURE 19 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 20 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS SEGMENT TO DOMINATE THE MARKET IN 2019
  • FIGURE 21 CAPTIVE MANUFACTURERS SEGMENT TO DOMINATE THE MARKET IN 2019
  • FIGURE 22 SYNTHETIC APIS TO DOMINATE THE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET DURING THE FORECAST PERIOD
  • FIGURE 23 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG
  • FIGURE 24 LOW-TO-MODERATE SEGMENT TO DOMINATE THE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, IN 2019
  • FIGURE 25 COMMUNICABLE DISEASES TO DOMINATE THE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET IN 2019
  • FIGURE 26 NORTH AMERICA: MARKET SNAPSHOT
  • FIGURE 27 EUROPE: MARKET SNAPSHOT
  • FIGURE 28 EXPANSIONS-KEY GROWTH STRATEGY ADOPTED BY MARKET PLAYERS FROM 2015 TO OCTOBER 2018
  • FIGURE 29 COMPETITIVE LEADERSHIP MAPPING OF THE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET - OVERALL MARKET
  • FIGURE 30 COMPETITIVE LEADERSHIP MAPPING OF THE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET - START-UP/SME
  • FIGURE 31 PFIZER, INC.: COMPANY SNAPSHOT (2017)
  • FIGURE 32 NOVARTIS AG: COMPANY SNAPSHOT (2017)
  • FIGURE 33 SANOFI: COMPANY SNAPSHOT (2017)
  • FIGURE 34 BOEHRINGER INGELHEIM: COMPANY SNAPSHOT (2017)
  • FIGURE 35 BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT (2017)
  • FIGURE 36 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2017)
  • FIGURE 37 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2017)
  • FIGURE 38 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2017)
  • FIGURE 39 MERCK & CO., INC.: COMPANY SNAPSHOT (2017)
  • FIGURE 40 ABBVIE INC.: COMPANY SNAPSHOT (2017)
  • FIGURE 41 F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT (2017)
  • FIGURE 42 ASTRAZENECA: COMPANY SNAPSHOT (2017)
目次
Product Code: PH 1262

"Increasing incidence of chronic diseases and technological advancements in API manufacturing are expected to drive the overall growth of the global APIs market."

The global APIs market is estimated to reach USD 245.2 billion by 2024 from USD 182.2 billion in 2019, at a CAGR of 6.1% during the forecast period. The increasing incidence of chronic diseases, growing importance of generics, and the increasing uptake of biopharmaceuticals are some of the major factors driving the growth of the global APIs market. On the other hand, the unfavorable drug price control policies across various countries and the increasing penetration of counterfeit drugs are expected to restrain the growth of this market in the coming years.

The biotech APIs segment is expected to grow at the highest CAGR during the forecast period.

On the basis of type of synthesis, the APIs market is categorized into synthetic APIs and biotech APIs. The synthetic APIs segment is estimated to account for the largest share in 2019. However, the biotech APIs segment is expected to grow at a higher rate over the forecast period. Factors such as growing demand of biotech drugs due to their specificity in action, advancements in biotechnology, increase in demand for monoclonal antibodies, and their similarity with the natural biological compounds found in the human body influence the growth of this segment.

The monoclonal antibodies segment is expected to account for the largest share of the global biotech APIs market.

Based on product, the biotech APIs market is segmented into monoclonal antibodies, hormones & growth factors, cytokines, fusion proteins, therapeutic enzymes, recombinant vaccines, and blood factors. In 2019, the monoclonal antibodies segment is estimated to account for the largest share of the biotech APIs market. Factors such as the increasing incidence of cancer, increasing investments in R&D, technological advances in genetic sequencing and target gene selection, and reduced side effects as compared to chemotherapy are responsible for driving this market.

North America to dominate the market during the forecast period.

In 2019, North America is expected to dominate the market, followed by Europe. The major factors driving the overall growth of the APIs market in this region include the growing incidence of preventable chronic diseases, increasing government focus on generic drugs, rising demand for biologics and specialty drugs, and technological advancements in the manufacturing processes of APIs. This market segment is expected to grow at a modest rate due to a combination of economic and healthcare severity measures and the introduction of low-cost, generic versions of branded drugs.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type - Tier 1: 37%, Tier 2: 22%, Tier 3: 41%
  • By Designation - C-level: 25%, D-level: 20%, Others: 55%
  • By Region - North America: 40%, Europe: 27%, Asia: 20%, RoW: 13%

List of Companies Profiled in the Report:

  • Pfizer, Inc. (US)
  • Novartis AG (Switzerland)
  • Sanofi (France)
  • Boehringer Ingelheim (Germany)
  • Bristol-Myers Squibb (US)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Eli Lilly and Company (US)
  • GlaxoSmithKline plc (UK)
  • Merck & Co., Inc. (US)
  • AbbVie Inc. (US)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • AstraZeneca plc (UK)

Research Coverage:

This report provides a picture of the global APIs market. It aims at estimating the size and future growth potential of the market across different segments, such as type, type of manufacturer, type of synthesis, type of drug, therapeutic application, and region. Furthermore, the report also includes an in-depth competitive analysis of key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them the closest approximations of the revenue numbers for the overall APIs market and its subsegments. Also, this report will help stakeholders to better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. It will also enable stakeholders to understand the pulse of the market and provide them with information on key market drivers, restraints, challenges, and opportunities.

TABLE OF CONTENTS

1 INTRODUCTION 26

  • 1.1 OBJECTIVES OF THE STUDY 26
  • 1.2 MARKET DEFINITION 26
  • 1.3 MARKET SCOPE 27
    • 1.3.1 MARKETS COVERED 27
    • 1.3.2 YEARS CONSIDERED FOR THE STUDY 28
  • 1.4 CURRENCY 29
  • 1.5 LIMITATIONS 29
  • 1.6 STAKEHOLDERS 29

2 RESEARCH METHODOLOGY 30

  • 2.1 RESEARCH DATA 30
    • 2.1.1 SECONDARY SOURCES 31
      • 2.1.1.1 Key Data from Secondary Sources 31
    • 2.1.2 PRIMARY SOURCES 32
      • 2.1.2.1 Key Data from Primary Sources 33
      • 2.1.2.2 Key Industry Insights 34
  • 2.2 MARKET SIZE ESTIMATION 35
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 37
  • 2.4 MARKET SHARE ESTIMATION 38
  • 2.5 ASSUMPTIONS FOR THE STUDY 38

3 EXECUTIVE SUMMARY 39

4 PREMIUM INSIGHTS 44

  • 4.1 ACTIVE PHARMACEUTICAL INGREDIENTS: MARKET OVERVIEW 44
  • 4.2 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE 45
  • 4.3 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER 45
  • 4.4 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS 46
  • 4.5 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG 47
  • 4.6 GEOGRAPHIC SNAPSHOT: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 47

5 MARKET OVERVIEW 48

  • 5.1 INTRODUCTION 48
  • 5.2 MARKET DYNAMICS 48
    • 5.2.1 DRIVERS 49
      • 5.2.1.1 Increasing incidence of chronic diseases 49
      • 5.2.1.2 Technological advancements in API manufacturing 50
      • 5.2.1.3 Growing importance of generics 50
      • 5.2.1.4 Increasing uptake of biopharmaceuticals 51
      • 5.2.1.5 Growing adoption of artificial intelligence-based tools for drug discovery 52
      • 5.2.1.6 Adoption of organ-on-chip models in drug development 53
      • 5.2.1.7 Growing focus on precision medicine 53
      • 5.2.1.8 Growing investments in real-world evidence by pharmaceutical companies 54
    • 5.2.2 RESTRAINTS 55
      • 5.2.2.1 Unfavorable drug price control policies across various countries 55
      • 5.2.2.2 Increasing penetration of counterfeit drugs 55
    • 5.2.3 OPPORTUNITIES 56
      • 5.2.3.1 Emerging biosimilars market 56
      • 5.2.3.2 Highly potent active pharmaceutical ingredients 56
      • 5.2.3.3 Emerging markets 57
      • 5.2.3.4 Emerging technologies 57
    • 5.2.4 CHALLENGES 57
      • 5.2.4.1 Product differentiation - A major concern for API manufacturers 57
      • 5.2.4.2 High manufacturing costs 58

6 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE 59

  • 6.1 INTRODUCTION 60
  • 6.2 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS 61
    • 6.2.1 GROWING NUMBER OF NEW MOLECULAR ENTITIES GAINING REGULATORY APPROVAL TO DRIVE MARKET GROWTH 61
  • 6.3 GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS 63
    • 6.3.1 GOVERNMENT INITIATIVES SUPPORTING THE ADOPTION OF GENERIC DRUGS TO BOOST MARKET GROWTH 63

7 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER 64

  • 7.1 INTRODUCTION 65
  • 7.2 CAPTIVE API MANUFACTURERS 66
    • 7.2.1 HIGH MANUFACTURING FLEXIBILITY AND ASSURANCE OF PRODUCT QUALITY HAVE DRIVEN FOCUS ON CAPTIVE MANUFACTURING 66
  • 7.3 MERCHANT API MANUFACTURERS 67
    • 7.3.1 MERCHANT API MANUFACTURERS MARKET, BY TYPE 68
      • 7.3.1.1 Merchant Innovative API Manufacturers 69
        • 7.3.1.1.1 Impending patent expiries and increasing costs of innovative drugs may restrain market growth 69
      • 7.3.1.2 Merchant Generic API Manufacturers 70
        • 7.3.1.2.1 Low manufacturing cost of generics likely to drive the growth of this segment 70

    • 7.3.2 MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS 70
      • 7.3.2.1 Merchant Synthetic API Manufacturers 71
        • 7.3.2.1.1 Need for specialized manufacturing capabilities has resulted in expansion among market players in this segment 71
      • 7.3.2.2 Merchant Biotech API Manufacturers 72
        • 7.3.2.2.1 Complexity of manufacturing biotech APIs has driven focus on partnerships between companies and CMOs 72

8 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS 74

  • 8.1 INTRODUCTION 75
  • 8.2 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS 76
    • 8.2.1 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE 77
      • 8.2.1.1 Innovative synthetic APIs 77
        • 8.2.1.1.1 The high value of innovative APIs to drive the growth of this segment 77
      • 8.2.1.2 Generic synthetic APIs 78
        • 8.2.1.2.1 Initiatives to promote the penetration of generics to bring down healthcare costs-a major growth driver 78
  • 8.3 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS 79
    • 8.3.1 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE 81
      • 8.3.1.1 Innovative biotech APIs 81
        • 8.3.1.1.1 Growing demand for innovative biopharmaceuticals to drive the market for this segment 81
      • 8.3.1.2 Generic biotech APIs 82
        • 8.3.1.2.1 Increasing demand for biosimilar drugs due to their cost-effectiveness to drive the growth of this segment 82
    • 8.3.2 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT 84
      • 8.3.2.1 Monoclonal antibodies 85
        • 8.3.2.1.1 Growing applications of antibody-drug conjugates in the treatment of cancer to drive the growth of this segment 85
      • 8.3.2.2 Hormones & growth factors 87
        • 8.3.2.2.1 The growing incidence of hormonal disorders to drive the market for this segment 87
      • 8.3.2.3 Cytokines 87
        • 8.3.2.3.1 Interferons and interleukins boost the immune system and have important applications in cancer treatment 87
      • 8.3.2.4 Fusion proteins 88
        • 8.3.2.4.1 Growing applications of Fc fusion proteins in biopharmaceuticals to drive the growth of this segment 88
      • 8.3.2.5 Recombinant vaccines 89
        • 8.3.2.5.1 Growing prevalence of infectious diseases has boosted vaccine development-a positive indicator of growth 89
      • 8.3.2.6 Therapeutic enzymes 90
        • 8.3.2.6.1 Growing significance of enzymes in therapies for cancer and pain management to drive the growth of this segment 90
      • 8.3.2.7 Blood factors 90
        • 8.3.2.7.1 Growing incidence of hemophilia to drive the growth of this segment 90
    • 8.3.3 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM 91
      • 8.3.3.1 Mammalian expression systems 92
        • 8.3.3.1.1 Ability of these systems to carry post-translational modification to drive the market for this segment 92
      • 8.3.3.2 Microbial expression systems 93
        • 8.3.3.2.1 Ability of these expression systems to provide high expression levels of proteins to drive the market for this segment 93
      • 8.3.3.3 Yeast expression systems 93
        • 8.3.3.3.1 Advantages such as efficient protein secretion, simple purification, and endotoxin-free products to boost demand 93
      • 8.3.3.4 Insect expression systems 94
        • 8.3.3.4.1 Efficient post-translational modifications provided by these systems to boost their demand 94
      • 8.3.3.5 Other expression systems 95

9 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG 96

  • 9.1 INTRODUCTION 97
  • 9.2 PRESCRIPTION DRUGS 98
    • 9.2.1 GROWING DISEASE PREVALENCE IS EXPECTED TO DRIVE THE PRESCRIPTION DRUGS MARKET 98
  • 9.3 OVER-THE-COUNTER DRUGS 99
    • 9.3.1 SALES OF OTC DRUGS HAVE RISEN DUE TO INNOVATIONS, PROMOTION OF SELF-MEDICATION, AND INCREASED ACCESS 99
  • 9.4 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY 100
    • 9.4.1 LOW-TO-MODERATE POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS 100
    • 9.4.2 POTENT-TO-HIGHLY POTENT ACTIVE PHARMACEUTICAL INGREDIENTS 101

10 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION 103

  • 10.1 INTRODUCTION 104
  • 10.2 COMMUNICABLE DISEASES 105
    • 10.2.1 GLOBAL HEALTH IMPACT OF COMMUNICABLE DISEASES AND INCREASING ANTIMICROBIAL RESISTANCE-KEY MARKET DRIVERS 105
  • 10.3 ONCOLOGY 106
    • 10.3.1 INCREASE IN GLOBAL SPENDING ON CANCER MEDICATION TO BOOST THE MARKET FOR THIS SEGMENT 106
  • 10.4 PAIN MANAGEMENT 108
    • 10.4.1 INCREASING DEMAND FOR INNOVATIVE AND ADVANCED PAIN MEDICATIONS IS A MAJOR GROWTH DRIVER FOR THIS MARKET 108

  • 10.5 CARDIOVASCULAR DISEASES 109
    • 10.5.1 GROWING INCIDENCE OF CARDIOVASCULAR DISEASES OWING TO SEDENTARY LIFESTYLES IS A MAJOR GROWTH DRIVER 109
  • 10.6 DIABETES 110
    • 10.6.1 HIGH GLOBAL PREVALENCE OF DIABETES TO DRIVE THE GROWTH OF THIS SEGMENT 110
  • 10.7 RESPIRATORY DISEASES 111
    • 10.7.1 HIGH GLOBAL PREVALENCE OF RESPIRATORY DISEASES TO DRIVE THE GROWTH OF THIS SEGMENT 111
  • 10.8 OTHER THERAPEUTIC APPLICATIONS 111

11 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION 113

  • 11.1 INTRODUCTION 114
  • 11.2 NORTH AMERICA 114
    • 11.2.1 US 121
      • 11.2.1.1 Increasing expenditure on medicine is expected to drive the APIs market in the US 121
    • 11.2.2 CANADA 126
      • 11.2.2.1 Support from government organizations is driving the growth of the APIs market in Canada 126
  • 11.3 EUROPE 130
    • 11.3.1 GERMANY 137
      • 11.3.1.1 Germany to dominate the market in Europe 137
    • 11.3.2 FRANCE 142
      • 11.3.2.1 Emergence of pharmerging markets in Asia may hinder market growth in France 142
    • 11.3.3 UK 147
      • 11.3.3.1 Growing adoption of generics will drive the growth of the UK market 147
    • 11.3.4 ITALY 152
      • 11.3.4.1 Italy's share in the global merchant APIs market is expected to remain stable over the forecast period 152
    • 11.3.5 SPAIN 157
      • 11.3.5.1 Spanish market has been typically dominated by branded drugs 157
    • 11.3.6 REST OF EUROPE 162
  • 11.4 ASIA 166
    • 11.4.1 JAPAN 172
      • 11.4.1.1 Japanese government aims to boost the use of generics by 2020 172
    • 11.4.2 CHINA 177
      • 11.4.2.1 Government policies to increase medicine access and affordability will support market growth 177
    • 11.4.3 INDIA 181
      • 11.4.3.1 India is a leading producer of generics 181

    • 11.4.4 SOUTH KOREA 186
      • 11.4.4.1 Government initiatives to introduce full medical coverage for major chronic diseases likely to drive this market 186
    • 11.4.5 REST OF ASIA 190
  • 11.5 REST OF THE WORLD 195

12 COMPETITIVE LANDSCAPE 200

  • 12.1 OVERVIEW 200
  • 12.2 MARKET PLAYER RANKING 202
  • 12.3 COMPETITIVE LEADERSHIP MAPPING - OVERALL MARKET 204
    • 12.3.1 VANGUARDS 204
    • 12.3.2 DYNAMIC DIFFERENTIATORS 204
    • 12.3.3 INNOVATORS 204
    • 12.3.4 EMERGING PLAYERS 204
  • 12.4 COMPETITIVE LEADERSHIP MAPPING - START-UP/SME 206
    • 12.4.1 PROGRESSIVE COMPANIES 206
    • 12.4.2 STARTING BLOCKS 206
    • 12.4.3 RESPONSIVE COMPANIES 206
    • 12.4.4 DYNAMIC COMPANIES 206
  • 12.5 COMPETITIVE SITUATION AND TRENDS 206
    • 12.5.1 PRODUCT LAUNCHES 207
    • 12.5.2 EXPANSIONS 208
    • 12.5.3 ACQUISITIONS 208
    • 12.5.4 OTHER STRATEGIES 209

13 COMPANY PROFILES 210

(Business overview, Products offered, Recent Developments, MNM view)*

  • 13.1 PFIZER, INC. 210
  • 13.2 NOVARTIS AG 213
  • 13.3 SANOFI 216
  • 13.4 BOEHRINGER INGELHEIM 220
  • 13.5 BRISTOL-MYERS SQUIBB 223
  • 13.6 TEVA PHARMACEUTICAL INDUSTRIES LTD. 227
  • 13.7 ELI LILLY AND COMPANY 230
  • 13.8 GLAXOSMITHKLINE PLC 233
  • 13.9 MERCK & CO., INC. 236
  • 13.10 ABBVIE INC. 239
  • 13.11 F. HOFFMANN-LA ROCHE 243
  • 13.12 ASTRAZENECA 245

Details on Business overview, Products offered, Recent Developments, SWOT analysis, MNM view might not be captured in case of unlisted companies.

14 APPENDIX 247

  • 14.1 DISCUSSION GUIDE 247
  • 14.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL 251
  • 14.3 AVAILABLE CUSTOMIZATIONS 253
  • 14.4 RELATED REPORTS 253
  • 14.5 AUTHOR DETAILS 254
Back to Top